Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Other Non-Current Assets (2019 - 2025)

Historic Other Non-Current Assets for Bolt Biotherapeutics (BOLT) over the last 7 years, with Q3 2025 value amounting to $981000.0.

  • Bolt Biotherapeutics' Other Non-Current Assets fell 3868.75% to $981000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $981000.0, marking a year-over-year decrease of 3868.75%. This contributed to the annual value of $981000.0 for FY2024, which is 4612.85% down from last year.
  • According to the latest figures from Q3 2025, Bolt Biotherapeutics' Other Non-Current Assets is $981000.0, which was down 3868.75% from $981000.0 recorded in Q2 2025.
  • Bolt Biotherapeutics' 5-year Other Non-Current Assets high stood at $1.8 million for Q4 2023, and its period low was $981000.0 during Q4 2024.
  • Moreover, its 5-year median value for Other Non-Current Assets was $1.6 million (2021), whereas its average is $1.5 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 1381.25% in 2023, then crashed by 4612.85% in 2024.
  • Over the past 5 years, Bolt Biotherapeutics' Other Non-Current Assets (Quarter) stood at $1.6 million in 2021, then changed by 0.0% to $1.6 million in 2022, then rose by 13.81% to $1.8 million in 2023, then tumbled by 46.13% to $981000.0 in 2024, then changed by 0.0% to $981000.0 in 2025.
  • Its Other Non-Current Assets was $981000.0 in Q3 2025, compared to $981000.0 in Q2 2025 and $981000.0 in Q1 2025.